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ABSTRACT 
 
Background 
Alkaptonuria (AKU) is a serious genetic disease characterized by premature spondyloarthropathy. 
Homogentisate-lowering therapy is being investigated for AKU. Nitisinone decreases homogentisic acid 
(HGA) in AKU but the dose-response relationship has not been previously studied.   
Methods 
SONIA 1 was an international, multicenter, randomized, open-label, no-treatment controlled, parallel-group, 
dose-response study. The primary objective was to investigate the effect of different doses of once daily 
nitisinone on 24-hour urinary HGA excretion (u-HGA24) in patients with AKU after 4 weeks of treatment. 
Forty patients were randomized into 5 groups of 8 patients each, with groups receiving no treatment or 1, 2, 4 
and 8 mg of nitisinone.  
Findings 
A clear dose-response relationship was observed between nitisinone and the urinary excretion of HGA. At 4 
weeks, the adjusted mean u-HGA24 was 31152, 3846, 1668, 686 and 327 µmol for the no treatment or 1, 2, 4 
and 8 mg doses respectively. 
For the most efficacious dose, 8 mg daily, this corresponds to a mean reduction of u-HGA24 of 98·8% 
compared to baseline.  An increase in tyrosine levels was seen at all doses but the dose-response relationship 
was less clear than the effect on HGA. Despite tyrosinaemia, there were no safety concerns and no serious 
adverse events were reported over the 4 weeks of nitisinone therapy. 
Conclusion 
In this study in AKU patients, nitisinone therapy decreased urinary HGA excretion to low levels in a dose-
dependent manner and was well tolerated within the studied dose range. 
Funding 
The research was supported by European Commission Seventh Framework Programme funding granted in 
2012 (DevelopAKUre, project number: 304985). 
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INTRODUCTION 
Alkaptonuria (AKU) is a serious, autosomal recessive, multisystem disorder [1-3] affecting approximately 
one in every 250,000 people [4], although some countries such as Slovakia and the Dominican Republic have 
a higher prevalence rate of around one in 19,000 [5,6].  Morbidity in AKU is caused by increased levels of 
homogentisic acid (2,5-dihydroxyphenylacetic acid, HGA) due to a deficient enzyme, homogentisate 1,2-
dioxygenase (HGD) [7].  Despite efficient urinary excretion of the HGA [4], some of it is oxidized to a 
melanin-like polymeric pigment via benzoquinone acetic acid (BQA).  This pigment polymer is deposited in 
connective tissues, particularly cartilage, a process termed ochronosis [8], leading especially to severe 
premature arthritis with an early onset, affecting the spine and synovial joints, large and small 3,4].  
 
Current treatments are limited to palliative analgesia and arthroplasty [9].  Nitisinone , is a competitive 
inhibitor of the enzyme 4-hydroxyphenyl-pyruvate dioxygenase (HPPD), decreasing the formation of HGA 
[10,11].  It is hypothesized that if HGA levels are reduced before the onset of overt ochronosis, this might 
prevent the development of the debilitating features of the disease. While nitisinone has been shown to reduce 
plasma HGA levels and urinary excretion in patients with AKU [12,13], and in a mouse model of AKU [14], 
it has not undergone any formal clinical development for AKU although three published investigator-initiated 
studies have been completed [4,12,13]. The 3-year study by Introne et al showed a significant reduction in 
urine HGA concentrations by about 95% using a daily dose of 2 mg of nitisinone but no significant effect on 
clinical parameters [13]. One possible factor for the inconclusive effect on clinical parameters may be the use 
of a sub-optimal dose.  
 
SONIA 1 is part of the DevelopAKUre program, which has received funding from the European Union 
Seventh Framework Program (FP7).  The objective of the clinical development program is to investigate the 
possibility of an effective and safe treatment of AKU.  
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The present study was designed to investigate the relationship between different doses of nitisinone and u-
HGA24.  A separate study of u-HGA24 in non-AKU patients was performed in parallel in order to define normal 
ranges [15]. 
 
METHODS 
Patients 
Patients with a well-documented AKU verified by increased urine HGA excretion and who were at least 18 
years old were eligible for inclusion in the study. Details of inclusion and exclusion criteria are described in 
the supplementary appendix (Table S1). In all patients, diagnosis of AKU was confirmed by HGD gene 
mutation identification performed during the study (data not shown). 
 
Study Design and Intervention 
SONIA 1 was a randomized, open-label, parallel-group study with a no-treatment control group. Patients were 
randomized to receive either 1, 2, 4 or 8 mg nitisinone once daily or no treatment (control). Forty patients 
were randomized, equally distributed amongst the groups (8 patients per group). The study design is 
summarized in Figure 1.  
 
The study was open label, since it is not feasible to blind a study with HGA-lowering treatment in AKU. One 
of the cardinal signs of AKU is urine darkening on standing as HGA is oxidized. Patients could therefore 
easily know whether they were on nitisinone or not. Furthermore, any personnel involved at the investigative 
sites who were involved in the processing of urine samples would also be able to see this difference. Since 
this study used objective assessments of  efficacy (changes in HGA levels), the open design was unlikely to 
have introduced bias.  The only subjective reporting in the study was that of adverse events.  Patients were 
requested to maintain stable dietary habits during the 4-week study period in order not to change their dietary 
protein intake. 
 
Rationale for dose selection 
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The choice of doses used in the study was based on current knowledge regarding the HGA-lowering effect of 
nitisinone. In one study, mean u-HGA24 was reduced from 4 g/day to 230 mg/day using a dose of 2·1 mg of 
nitisinone daily [12].  In a 3-year study, using a dose of 2 mg daily, mean u-HGA24 was decreased from 5·1 
g/day to values ranging from 113 to 203 mg/day during the course of the study, which on average corresponded 
to a 95% decrease [13].  We wanted to investigate the effect of nitisinone on HGA at higher doses than the 
ones used in previous studies.  At the same time, we were interested in determining the effect of nitisinone on 
serum tyrosine levels at a dose lower than 2 mg daily. Therefore, doses of 1, 2, 4 and 8 mg were used in this 
study.  The daily dosing frequency is based on the long half-life of nitisinone [11]. 
A suspension of nitisinone (Orfadin®) containing 4 mg/mL administered in the morning was used as it allowed 
easy administration of the selected doses.  
 
Randomization procedures 
Patients were randomly assigned to one of five groups, in a 1:1:1:1:1 ratio stratified by study centre using 
randomly permuted blocks. Results for HGA and tyrosine were not accessible to the medical monitors, sponsor 
personnel, or study site personnel until study completion. 
 
Prior and concomitant therapy 
Patients were allowed to continue on any chronic medication and any changes during the study were recorded, 
from the time of the screening and randomization visit until the follow-up telephone call. Patients were not 
allowed to have used nitisinone within the 60 days prior to randomization. 
 
Treatment compliance 
Product accountability records were kept by the pharmacy and investigator. All unused IMP was returned to 
the clinical study sites and measured. The amount consumed was compared to the expected consumption for 
the randomized dose.  
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Chemical measurements 
Urine sample collection and handling 
At baseline, and weeks 2 and 4, urine was collected over 24 hours into 2·5 L bottles containing 30 mL of 5N 
H2SO4 and stored away from bright light in cool conditions. The weight of the collected urine was recorded 
and used as the volume in the calculations of u-HGA24 assuming a density of 1g/mL. An aliquot of the 
collected urine was frozen and kept at -20ºC until analysis. 
 
Serum sample collection and handling 
Measurements of serum tyrosine (s-Tyr) and HGA (s-HGA) concentrations were performed at weeks 0, 2 and 
4. At each visit one sample was collected pre-dose in fasting patients. Blood samples were collected in non-
gel serum tubes. An aliquot of serum was immediately acidified using perchloric acid (10% v/v 5·8M), and 
kept frozen at -20ºC until analysis. 
 
Analyses of HGA and tyrosine 
The concentrations of tyrosine and HGA in serum and urine were measured by liquid chromatography tandem 
mass spectrometry [16,17]. All analyses were performed on an Agilent 6490 Triple Quadrupole mass 
spectrometer with Jet-Stream® electrospray ionisation (ESI-MS/MS) coupled with an Agilent 1290 infinity 
UHPLC pump and HTC autosampler.  This method incorporates reverse-phase chromatographic separation 
on an Atlantis C18 column (100mmx3·0mm, 3µm). Initial conditions of 80:20 water:methanol with 0·1% 
formic acid (v/v) increased linearly to 10:90 over five minutes. Matrix-matched calibration standards and 
quality controls were utilized with appropriate isotopically labelled internal standards.  Quantitation was 
achieved in multiple reaction mode (MRM) with two product ion transitions for both tyrosine (positive 
ionisation) and HGA (negative ionisation). Samples were prepared by dilution in a combined internal standard 
solution (final concentrations of 0·4µmol/L 13C6-HGA and 2µmol/L d2-tyrosine in 0·1% formic acid (v/v) in 
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deionised water). All serum and urine quantitation analysis were performed by the Department of Clinical 
Biochemistry and Metabolic Medicine at the Royal Liverpool University Hospital (RLUH).  
 
Endpoints 
The primary endpoint was the u-HGA24 in patients with AKU after 4 weeks of nitisinone treatment. Secondary 
endpoints supporting the primary objective included u-HGA24 after 2 weeks, as well as the u-HGA/u-
creatinine ratio at Weeks 2 and 4. 
Secondary endpoints included the pre-dose serum HGA concentration (s-HGA) and serum tyrosine 
concentration (s-Tyr) in patients with AKU at Weeks 2 and 4.  
 
Safety Assessment 
At each visit, adverse events (AEs) and laboratory values were recorded. Routine laboratory processes at each 
clinical study site were employed to measure biochemistry and haematology profiles. At each visit a corneal 
slit lamp examination was performed to check for possible corneal toxicity. 
 
Study oversight 
The study was conducted at two sites, Liverpool (United Kingdom) and Piešťany (Slovakia) from May to 
October 2013. Data were recorded by investigators at each site, collected, and monitored by the Contract 
Research Organization PSR Group (Amsterdam, Netherlands). The protocol and amendments were approved 
by the relevant ethics review boards and national regulatory authorities. Written informed consent was 
obtained from all patients before any study procedures. An external Data and Safety Monitoring Board was 
assigned to evaluate the safety data.  
 
Statistical analysis  
The primary variable u-HGA24 at Week 4 was analyzed using a mixed model for repeated measures (MMRM). 
The model included the study site, treatment group, visit, and the interaction between treatment group and 
visit as fixed factors and the baseline u-HGA24 as a covariate.  Model-based least square means and associated 
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95% confidence intervals for each treatment group were calculated. The analysis was conducted on the full 
analyses set (FAS). There were no missing data for the primary and secondary variables. Statistical analyses 
were carried out using SAS v9·3. 
 
Analysis of safety and tolerability data 
Adverse events 
All adverse events (AEs) during the study were coded using the Medical Dictionary for Regulatory Activities 
(MedDRA version 16·0). The incidence of adverse events were summarized in frequency tables.  The changes 
in safety laboratory parameters from baseline to all post-baseline visits were summarized by treatment group 
and visit using descriptive statistics.   
 
Role of the Funding Source 
This study was funded by grants from the European Union Framework Programme 7 which had no direct 
participation in any aspect of design and conduct of the study, drug supply or reporting. 
 
RESULTS 
Patients and Study Treatment 
15 and 25 patients with AKU from clinical study sites in Liverpool and Piešťany respectively were randomized 
into 5 groups (no treatment, 1, 2, 4 and 8 mg groups). All randomized patients completed the study. Patient 
demographics and baseline characteristics were similar across the 5 groups (Table 1). The majority (67·5%) 
were male, and the mean age for all patients was 47·2 years ranging from 19 to 63 years. 38 were Caucasian 
and 2 were Asian. Baseline s-HGA, s-Tyr and u-HGA24 are shown in Table 2.   
There were no protocol deviations that affected the interpretation of the results.  
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Table 1. SONIA 1 Demographic and baseline data [Mean (SD)]   
 Untreated 
(N=8) 
1 mg 
(N=8) 
2 mg 
(N=8) 
4 mg 
(N=8) 
8 mg 
(N=8) 
Total 
(N=40) 
P-
value* 
Age (years) 
 
45·9 (15·3) 44·4 
(10·9) 
43·9 
(13·7) 
47·3 
(10·7) 
54·4 (7·3) 47·2 
(11·9) 
0·3336 
Body weight (kg) 
 
71·0 (23·5) 86·9 
(15·9) 
74·6 
(10·9) 
76·9 
(14·3) 
81·1 
(13·7) 
78·1 
(16·3) 
0·2038 
Height (cm) 
 
165·3 
(12·1) 
170·6 
(7·1) 
167·1 
(9·4) 
168·4 
(5·9) 
165·9 
(6·7) 
167·5 
(8·3) 
0·7509 
Gender  n 
(%) 
Female 4 (50·0) 1(12·5) 3 (37·5) 3 (37·5) 2(25·0) 13(32·5) 0·7098 
 Male 4 (50·0) 7(87·5) 5 (62·5) 5 (62·5) 6(75·0) 27(67·5)  
Race  n (%) White 7 (87·5) 7(87·5) 8(100) 8 (100) 7(87·5) 37(92·5) 1·000 
 Asian 1 (12·5) 1(12·5) 0 (0·0) 0 (0·0) 0 (0·0) 2 (5·0)  
 Others 0 (0·0) 0 (0·0) 0 (0·0) 0 (0·0) 1(12·5) 1 (2·5)  
* P-values: Age/ Body Weight/ Height = Wilcoxon rank-sum – Kruskal Wallis, Gender, Race = Fisher’s 
exact test. 
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Table 2. Mean (SD) u-HGA24, u-HGA/creatinine, s-HGA and s-Tyr in untreated AKU patients and 
AKU patients receiving nitisinone 1, 2, 4 and 8 mg daily    
 Untreated N=8 
1 mg  
N=8 
2 mg  
N=8 
4 mg  
N=8 
8 mg  
N=8 
  u-HGA24  (µmol) 
Baseline 29836  (5067) 36757 (14614) 31440 (7388) 35453 
(13581) 
27354 
(5235) 
Week 4   31042 (4603) 3931 (1707) 1602 (842) 734 (430) 146 (51) 
u-HGA/creatinine (µmol/mol) 
Baseline  2827 (876) 2273 (315) 3074 (318) 2824 (368) 2703 (617) 
Week 4   2987 (916) 246 (85) 130 (43) 48·4 (28) 14·0 (5) 
s-HGA (µmol/L) 
Baseline  27·5 (8.9) 28 (11·1) 30·3 (7·7) 32·1 (6·6) 28·3 (7·8) 
Week 4   30·5(12·4) ND ND ND ND 
s-Tyr (µmol/L) 
Baseline  54 (15) 68 (20) 62 (10) 60 (9) 55 (5) 
Week 4   56 (15) 653 (106) 715 (171) 803 (155) 813 (145) 
ND = not determined (below 3·1 µmol/L); u-HGA24 urine HGA excretion over 24 hours; u-HGA/creatinine: 
urine HGA excretion adjusted per mol of urine creatine; s-HGA: serum HGA in acidified fasting pre-nitisinone 
sample; s-Tyr: serum tyrosine in fasting sample. 
 
Primary Endpoint 
Urinary HGA excretion 
Data for the 2- and 4-week visits are presented in Table 2, and in Figure 2a and b. 
The u-HGA24 before starting treatment was highly variable, and ranged from 14,443 to 69,503 µmol 
(corresponding to 2,426 to 11,677 mg) (Table 2).  
 
At Week 4, a clear dose-response relationship between nitisinone and u-HGA24 was observed (Table 2). The 
adjusted means and associated 95% confidence intervals were 31,152 (25,220 to 37,085), 3,846 (3,086 to 
4,606), 1,668 (926 to 2,409), 686 (0 to 1,438) and 327 (0 to 1,079) µmol for the untreated, 1, 2, 4, and 8 mg 
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doses, respectively. From the MMRM, treatment group was statistically significant (p<0·0001), site, visit, 
site-visit interaction and u-HGA24 were not significant (p values: 0·282, 0·609, 0·446, 0·077 respectively). 
All pairwise comparisons between groups at 4-weeks were statistically significant except for 3mg group v 
4mg group and 4mg group v 8mg group (p<0·0001 in all cases except for: 3mg v 4mg, p=0·067; 3mg v 8mg, 
p=0·014; 4mg v 8mg, p=0·504). A similar pattern was observed for pairwise comparisons at 2-weeks, the only 
non-significant result being between 4 mg and 8 mg group (p=0·145). Besides being the most effective dose 
the 8-mg dose also showed the least variability. Similar results were seen already at Week 2. The dose-
response relationship can be seen more clearly in Figure 2b, in which the baseline values and data for untreated 
patients have been omitted. Mean u-HGA24 was about 50 and 250 times higher in the 8 and 4-mg nitisinone 
dose groups respectively than the highest value observed in non-AKU subjects [15]. 
 
The u-HGA/u-creatinine ratios at baseline and week 4 are presented in Table 2. They confirm the results seen 
for the u-HGA24 values without creatinine correction, and indicate acceptably complete 24-hour urine 
collection. 
 
Secondary endpoint 
Serum HGA 
Serum HGA was quantifiable in all patients before starting nitisinone treatment. After treatment, s-HGA 
values were below the lower limit of quantification (LLOQ) (3·1 µmol/L) in 64 % of all samples collected in 
treated patients (Table 2). 
No comparison could be made with s-HGA in non-AKU subjects as all were below the LLOQ in that 
population [15]. 
 
Serum Tyrosine 
The s-Tyr data, pre-dose and after 4 weeks of treatment, are presented in Table 2 and Figure 3. Mean s-Tyr 
increased with dose in all patients post-nitisinone. With few exceptions, all nitisinone-treated patients had 
levels above 500 µmol/L, with the highest observation (1,117 µmol/L) seen for a patient in the 4-mg group. 
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Other safety results 
No safety concerns were identified in this 4-week study. Adverse events are summarized in Table S3. There 
were no SAEs and no event occurred in more than 1 patient, except for back pain that was reported by 2 
patients in different dose groups. All events were considered mild, except for back pain in one patient in the 
4-mg dose group. No signals from laboratory data were observed. No patient experienced any corneal effects 
of elevated tyrosine. (Supplementary appendix Tables S3). 
 
DISCUSSION 
There is currently no approved pharmacological therapy for AKU. Treatment therefore relies on palliative 
analgesia and joint replacement surgery. Current experience with nitisinone is limited to three studies carried 
out at the National Institutes of Health (NIH), USA [4,12,13]. The last nitisinone study carried out by the NIH, 
a 3-year outcomes study, was inconclusive for the rheumatological endpoint (hip rotation) [13]. One possible 
reason for the inconclusive NIH study is that an optimal dose may not have been used. We therefore 
investigated the HGA-lowering effect of different doses of nitisinone to find a dose that could lower u-HGA24 
to levels closer to what is seen in normal subjects.  
 
A clear dose-response relationship was observed for the effect of nitisinone on the urinary excretion of HGA. 
Excretion decreased consistently across the studied dose interval of 1 to 8 mg. In addition, the inter-subject 
variability decreased with increasing dose.  
In a separate study in normal subjects [15], u-HGA24 could only be determined in 7 out of 22 individuals. The 
remaining subjects had urine concentrations of HGA below the limit of quantitation. The highest amount of 
HGA excreted that was observed in a normal subject was 2·9 µmol/day. Thus, the adjusted mean value in the 
8-mg group (327 µmol) was still about 100 times higher than this value, and u-HGA24 was not normalized, 
even with the highest dose. Nevertheless, the 8-mg dose resulted in a mean reduction of u-HGA24 of 98·8 % 
compared to baseline. We estimate that a complete normalization of u-HGA24 would correspond to a reduction 
of approximately 99·99 %.  
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There is a lack of data correlating levels of serum and urine HGA with the evolution of AKU in patients. 
Therefore the level of HGA post-nitisinone that would prevent ochronosis if treatment is started sufficiently 
early, or the level that would arrest or delay ochronosis in humans if treatment is started later in AKU, is 
currently unknown. Lifetime treatment of AKU mice with nitisinone resulted in an 88% plasma HGA 
reduction and completely prevented ochronosis [14].  In the absence of such data in humans, it is reasonable 
to assume that the lower the serum and urine HGA, the more likely it is that ochronosis will be modulated. 
However, there must be a point at which further HGA reduction is of no relevance.  The effect of nitisinone 
on clinical symptoms and long-term safety needs to be further investigated. 
 
CONCLUSIONS 
Treatment of AKU patients with nitisinone at doses of 1 to 8 mg reduced u-HGA and s-HGA in a dose-
dependent manner. The least inter-patient variability was seen in the 8 mg dose group.  No safety concerns 
were raised from this short-term study. 
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Figures and legends 
Figure 1. SONIA 1 Study Design. 
The study consisted of two main periods: treatment, and follow-up. After screening, patients were 
randomized at baseline (1:1:1:1:1) to no treatment (control), and oral daily doses of nitisinone of 1, 2, 4 and 
8 mg. The treatment period consisted of 4 weeks, during which study drug was administered. At 6 weeks a 
follow up telephone call concluded the study.  (Abbreviations: S+R = Screening, Baseline and Randomization 
Visit; F= Final Treatment Visit; T = Telephone Follow-Up Visit)  
 
Figure 2. 
2a. Box-plots of 24-hour urinary excretion (µmol/24 hours) of HGA in untreated and nitisinone-treated 
AKU patients over time.  
2b. Box-plots of 24-hour urinary excretion (µmol/24 hours) of HGA in nitisinone-treated AKUpatients at 
weeks 2 and 4. The greatest reduction in uHGA24 with the least inter-patient variability was the 8 mg dose. 
An outlier has been excluded in the box plot but shown outside the box.   
 
Figure 3. Fasting pre-dose serum concentrations of tyrosine at Week 4 (all patients). There was increased 
tyrosine in all patients on nitisinone. There was a trend towards higher tyrosine with dose which was  
statistically significant (p=0.039). 
  
 
